EUVIMEDEUVIMED entdecken
Crossref

Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery

Jonathan S Auerbach, Ahmed Alnajar, Samira S Patel, Hayley B Gershengorn, Joseph Lamelas, Daitiara Perez, Oscar D Aljure, Tanira D Ferreira, Lazaro A Gonzalez, Jorge L Cabrera

Journal of Cardiothoracic and Vascular Anesthesia · 2025-06 · 39 (6) · 1441-1450

DOI: 10.1053/j.jvca.2025.02.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiothoracic and Vascular Anesthesia, 2025-06. Verfasst von Jonathan S Auerbach und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL. Electronic…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Ketoacidosis, Cardiac Surgical Procedures, Preoperative Care. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Outcomes of stopping sodium-glucose cotransporter 2 inhibitors (SGLT2i) 5 days before open heart surgery (euglycemic diabetic ketoacidosis [eDKA] rate, mortality, infection, hospital, and cardiovascular intensive care unit [CVICU] length of stay [LOS]). DESIGN: Retrospective study. SETTING: Academic university hospital. PARTICIPANTS: Adult open heart surgery patients. EXPOSURES: Patients on SGLT2i who stopped medications 5 days before open heart surgery versus non-SGLT2i-using patients. MEASUREMENTS AND MAIN RESULTS: We evaluated patients who were told to stop SGLT2i 5 days before receiving open heart surgery for eDKA development within 24 hours of hospital admission (12/14/2022 to 10/25/2023). Non-eDKA outcomes were compared between SGLT2i users and non-users using Wilcoxon rank sum and Chi-square testing as appropriate. Of 540 open heart surgery patients, 48 (8.9%) were prescribed SGLT2i's before surgery; of these, 0 (0%) developed eDKA within 24 hours of hospital admission. Hospital LOS was statistically longer for patients with SGLT2i use (median [interquartile range]: 4 [4-5] v 4 [3-6] days, p = 0.003; mean [standard deviation]: 4 [3] v 5 [2], p = 0.03). We found no significant difference between patients with and without SGLT2i use in CVICU LOS (median [interquartile range]: 1.67 [0.95-2.09] v 1.17 [0.96-1.88] days, p = 0.14), in-hospital mortality (2.1% [1] v 0.6% [3], p = 0.3), or sternal infections (0 [0.0%] v 2 [0.4%], p > 0.9). CONCLUSION: Postoperative eDKA was absent in SGLT2i patients told to stop medications 5 days before open heart surgery. LOS and infection and mortality rates appeared similar between the two cohorts. Stopping SGLT2i medications 5 days before open heart surgery appears safe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic KetoacidosisCardiac Surgical ProceduresPreoperative CareHumansRetrospective StudiesMaleFemaleMiddle AgedAgedTreatment OutcomeLength of StayBlood Glucose

Stichwörter der Autor:innen

cardiothoracic surgerydiabetic ketoacidosiseuglycemicinfectionslength of staymetabolic acidosismortality

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBlood Glucose

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL. Electronic address: jxa896@med.miami.edu.
  • Division of Cardiothoracic Surgery, Department of Surgery, University of Miami Miller School of Medicine, Miami, FL.
  • Care Transformation, University of Miami Hospital and Clinics, Miami, FL.
  • Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL; Division of Critical Care Medicine, Albert Einstein College of Medicine, Bronx,…
  • Pharmacy Department, University of Miami Miller School of Medicine, Miami, FL.
  • Department of Anesthesiology, University of Miami Miller School of Medicine, Miami, FL.

Zitieren

APA

Auerbach, J. S., Alnajar, A., Patel, S. S., Gershengorn, H. B., Lamelas, J., Perez, D., Aljure, O. D., Ferreira, T. D., Gonzalez, L. A., & Cabrera, J. L. (2025). Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 39(6), 1441-1450. https://doi.org/10.1053/j.jvca.2025.02.030

Vancouver

Auerbach JS, Alnajar A, Patel SS, Gershengorn HB, Lamelas J, Perez D, et al. Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery. Journal of Cardiothoracic and Vascular Anesthesia. 2025;39(6):1441-1450. doi:10.1053/j.jvca.2025.02.030

BibTeX
@article{Auerbach2025,
  author = {Auerbach, Jonathan S and Alnajar, Ahmed and Patel, Samira S and Gershengorn, Hayley B and Lamelas, Joseph and Perez, Daitiara and Aljure, Oscar D and Ferreira, Tanira D and Gonzalez, Lazaro A and Cabrera, Jorge L},
  title = {Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery},
  journal = {Journal of Cardiothoracic and Vascular Anesthesia},
  year = {2025},
  volume = {39},
  number = {6},
  pages = {1441--1450},
  doi = {10.1053/j.jvca.2025.02.030}
}
Kostenlos starten →